Fig 1: EGF stimulation enhances the interaction between EGFR, EPS8, and SCAMP3 in androgen-sensitive and enzalutamide-resistant prostate cancer cells. The physical interactions between EGFR, EPS8, SCAMP3, and AR-V7 were assessed by co-immunoprecipitation (co-IP) assays in LNCap and LNCap-Enz cells with or without EGF stimulation (100 ng/ml, 24 h). (A) Representative western blot following immunoprecipitation with anti-EGFR antibody in LNCap cells, showing enhanced association of EPS8, SCAMP3, and AR-V7 with EGFR after EGF treatment. (B) Densitometric quantification of EPS8, SCAMP3, and AR-V7 protein levels from panel A, normalized to control and presented as percentage [mean±standard deviation (SD), *p<0.05, one-way ANOVA followed by Tukey’s post hoc test]. (C) Representative western blot following immunoprecipitation with anti-SCAMP3 antibody in LNCap cells, demonstrating increased binding of EPS8, EGFR, and AR-V7 with SCAMP3 after EGF stimulation. (D) Quantitative analysis of protein expression from panel C, showing significant up-regulation of EPS8 and EGFR but down-regulation of AR-V7 in EGF-treated samples (*p<0.05, one-way ANOVA followed by Tukey’s post hoc test). (E) Co-IP results using anti-EGFR antibody in LNCap-Enz cells, revealing enhanced interaction of EGFR with EPS8, SCAMP3, and AR-V7 following EGF treatment. (F) Densitometric analysis of protein expression from panel E, indicating significant increases in all three proteins (*p<0.05, one-way ANOVA followed by Tukey’s post hoc test). (G) Western blot analysis following immunoprecipitation with anti-SCAMP3 antibody in LNCap-Enz cells, showing enhanced association of EPS8 and EGFR but decreased AR-V7 binding with SCAMP3 after EGF stimulation. (H) Quantitative assessment of protein levels from panel G, demonstrating significant up-regulation of EPS8 and EGFR but down-regulation of AR-V7 in the presence of EGF (*p<0.05, one-way ANOVA followed by Tukey’s post hoc test). IB: Immunoblotting; IP: immunoprecipitation.
Fig 2: Schematic model illustrating the cooperative regulation of EGFR signaling by SCAMP3 and EPS8 in enzalutamide-resistant prostate cancer cells. Upon EGF stimulation, EGFR forms a complex with EPS8 and SCAMP3, promoting downstream activation of STAT3, AKT, and ERK signaling pathways. This effect is more prominent in enzalutamide-resistant LNCap (LNCap–Enz-R) cells compared to parental LNCap cells. Genetic inhibition using shRNA targeting SCAMP3 or EPS8 suppresses this pathway, whereas overexpression via pcDNA transfection enhances EGFR signaling activity. These findings suggest that SCAMP3 and EPS8 act synergistically to modulate EGFR-mediated resistance signaling in advanced prostate cancer.
Fig 3: EGF stimulation enhances the expression of EGFR, EPS8, SCAMP3, and AR-V7 in androgen-sensitive and enzalutamide-resistant prostate cancer cells. The effects of epidermal growth factor (EGF) on the expression of EGFR, EPS8, SCAMP3, and AR-V7 were examined in LNCap and LNCap-Enz cells. (A) Representative western blot analysis of LNCap cells treated with or without EGF (100 ng/ml) for 24 h, showing the protein expression levels of EGFR, EPS8, SCAMP3, AR-V7, and β-actin. (B) Densitometric quantification of EGFR, EPS8, SCAMP3, and AR-V7 protein expression in LNCap cells, normalized to β-actin and expressed as a percentage of control. EGF treatment significantly increased the expression of all four proteins (*p<0.05, one-way ANOVA followed by Tukey’s post hoc test). (C) Cell viability assay showing that EGF treatment modestly increased LNCap cell viability compared to control conditions. (D) Representative western blot analysis of LNCap-Enz cells treated with or without EGF (100 ng/ml), demonstrating up-regulation of EGFR, EPS8, SCAMP3, and AR-V7 protein levels. (E) Quantitative analysis of protein expression in LNCap-Enz cells, showing significant increases in EGFR, EPS8, SCAMP3, and AR-V7 levels following EGF stimulation (*p<0.05, one-way ANOVA followed by Tukey’s post hoc test). (F) Cell viability assay revealing a slight increase in LNCap-Enz cell viability after EGF treatment. Data are presented as mean±standard deviation (SD) from three independent experiments.
Fig 4: EPS8 regulates the EGFR and SCAMP3 signaling pathway in prostate cancer cells. The effect of EPS8 overexpression on EGFR and SCAMP3 signaling was investigated in androgen-sensitive and enzalutamide-resistant prostate cancer cells. (A) Representative western blot analysis of LNCap cells treated with EGF (100 ng/ml) alone, or transfected with pcDNA-control plus EGF, or transfected with pcDNA-EPS8 plus EGF. Protein expression levels of EGFR, SCAMP3, EPS8, and downstream signaling molecules STAT3, AKT, and ERK were detected. β-actin served as a loading control. (B) Densitometric analysis of protein expression in LNCap cells from three independent experiments. Data are presented as percentage of control [mean±standard deviation (SD)]. Asterisks indicate statistically significant differences compared to control (*p<0.05, one-way ANOVA followed by Tukey’s post hoc test). (C) Representative western blot analysis of LNCap-Enz cells under the same experimental conditions as in panel A. (D) Quantitative analysis of protein expression in LNCap-Enz cells showing relative protein levels normalized to β-actin.
Fig 5: EPS8 and SCAMP3 enhance the migratory ability of LNCaP and LNCaP-Enz cells. (A, C) Representative phase-contrast images from wound healing assays in LNCaP (A) and LNCaP-Enz (C) cells transfected with pcDNA-control, pcDNA-EPS8, or pcDNA-SCAMP3. Images were acquired at 0 and 12 hours after ibidi insert removal. (B, D) Quantification of migration area (%) in LNCaP (B) and LNCaP-Enz (D) cells at 12 hours. Data represent the mean±standard deviation (SD) from three independent experiments. *p<0.05 vs. control group using one-way ANOVA followed by Tukey’s post hoc test.
Supplier Page from OriGene Technologies for EPS8 Human shRNA Plasmid Kit (Locus ID 2059)